NCT07396454 2026-02-09
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06874933 2025-08-12
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06992336 2025-05-28
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06331169 2024-08-30
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Fudan University
Phase 1 Recruiting
NCT05075512 2021-10-12
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Recruiting